Informed Consent in Medicine: Your Legal Right to Know

Educational content only. Nothing here is medical advice, diagnosis, or treatment, and none of it is a recommendation to start, stop, or change any medication or procedure. Bring your own health decisions to a qualified provider who knows your history.

Key takeaways

• Informed consent is a legal duty, not a form. It requires disclosure of the diagnosis, the risks, the benefits, the alternatives, and the option to decline.
• Most states apply the reasonable patient standard, meaning your provider must tell you what a reasonable patient would want to know rather than what is customary in their specialty.
• The requirement came out of the Nuremberg Doctors' Trial in 1947 and was reinforced by Kefauver-Harris, Helsinki, and the Belmont Report.
• The FDA package insert is public and free at DailyMed. The pamphlet handed out in the office is marketing material and is not the same document.
• Thalidomide, Vioxx, breast implants, and LASIK all involved risk information that existed at the time and was not passed on.
• A trial's control arm determines what its data can support. Where no unexposed group was enrolled, relative safety claims are not coming from that trial.

Legal definition History Why it matters now When consent fails The placebo problem In herbal practice What to ask FAQ

Informed consent is not a formality, and it is not the clipboard you sign in the waiting room. It is a legal duty owed to you by anyone who treats your body, and it carries a specific meaning that most patients have never been told.

The duty exists because of what happened when it did not. Understanding where it came from, what it actually requires, and how often it goes unmet changes how you walk into an appointment.

What Is the Legal Definition of Informed Consent?

In US medical law, informed consent means a competent patient voluntarily agrees to a treatment after receiving enough information to weigh it against the alternatives. Courts and federal regulation break the required disclosure into these elements:

• The diagnosis and the nature of the proposed treatment or procedure.
• The risks, including those that are rare but serious.
• The expected benefits, and how likely they are.
• Reasonable alternatives, including their own risks and benefits.
• The option to decline, and what happens if you do.

Two standards govern how much must be disclosed. Under the older physician standard, a provider must tell you what a reasonable physician in that specialty would tell you. Under the reasonable patient standard, adopted by most states following Canterbury v. Spence in 1972, a provider must tell you what a reasonable patient would want to know before deciding. The second standard is the more protective of the two, because it measures disclosure against your need to decide rather than against professional custom.

Consent obtained through pressure, incomplete information, or misrepresentation is not valid consent, which means a signature on a form is evidence that a conversation happened rather than proof that it was adequate.

Where Did Informed Consent Come From?

The concept has roots in American common law well before it had a name. In 1914, Justice Benjamin Cardozo wrote in Schloendorff v. Society of New York Hospital that every adult of sound mind has the right to determine what is done with his own body, and that a surgeon who operates without consent commits an assault. That established bodily autonomy as a legal principle, though it did not yet require any disclosure of risk.

The disclosure requirement came out of atrocity. At the Nuremberg Doctors' Trial in 1947, twenty-three German physicians and administrators were tried for experiments conducted on concentration camp prisoners without their agreement. The verdict included a ten-point statement of research ethics now called the Nuremberg Code, and its first line is unambiguous: the voluntary consent of the human subject is absolutely essential. The Code specified that a subject must have legal capacity, must be free from coercion or duress, and must have sufficient knowledge of the experiment to make an understanding decision.

From there the principle moved into medicine proper. The World Medical Association adopted the Declaration of Helsinki in 1964, extending consent requirements to clinical research. In 1957, a California appellate court in Salgo v. Leland Stanford Jr. University Board of Trustees used the phrase "informed consent" for the first time and held that a physician has a duty to disclose the facts necessary to an intelligent decision, and Canterbury set the patient-centered standard fifteen years after that. The Belmont Report of 1979, written after the Tuskegee syphilis study was exposed, laid out respect for persons, beneficence, and justice as the ethical foundation for research on human subjects.

Federal regulation followed. Under 21 CFR 50.25, the FDA requires specific disclosures for anyone enrolled in a clinical trial, while state law governs consent in ordinary clinical care, and every state requires it in some form.

---

Need Something From the Shop??

Check out these handmade, holistic and/or herbal goods and support our work to provide accessible health information to the masses!

---

Why Informed Consent Matters More Now

The legal framework has not weakened. What has changed is the environment in which drugs reach the market and the amount of time providers are given to explain them.

Approvals Based on Incomplete Data

The FDA's accelerated approval pathway allows a drug to reach market based on a surrogate endpoint, meaning a lab value or imaging result thought to predict benefit rather than a demonstrated improvement in how patients feel or how long they live. The manufacturer is then required to run a confirmatory trial, and reviews by the Government Accountability Office and the HHS Office of Inspector General have repeatedly found that these confirmatory trials run years behind schedule, with some never completed at all.

Makena, approved in 2011 to reduce preterm birth, stayed on the market for twelve years before its confirmatory trial failed and it was withdrawn in 2023. Aducanumab was approved for Alzheimer's disease in 2021 over the objection of the FDA's own advisory committee, and three committee members resigned in protest. In both cases patients took a drug for years under the reasonable assumption that approval meant proven benefit.

Black Box Warnings That Go Unmentioned

A boxed warning is the strongest safety alert the FDA issues, reserved for risks that can cause serious injury or death, and it appears at the top of the prescribing information inside a black border. Patients are regularly prescribed drugs carrying these warnings without ever hearing that the warning exists, which is difficult to reconcile with any standard of disclosure.

Fifteen Minutes

Many practices schedule fifteen to twenty minutes of face-to-face time per patient. In that window a physician is expected to take a history, examine, reach a working diagnosis, choose a treatment, document the encounter, and obtain informed consent. That is not enough time, and most physicians know it, because the problem is structural rather than personal and is driven by billing models and volume targets set well above the exam room. Self-pay and concierge practices with longer appointments tend to do better, though the gap still appears there.

The Insert Versus the Pamphlet

When patients ask for the FDA package insert, they are often handed a glossy patient information leaflet from the office instead, and these are not the same document. The package insert, also called the prescribing information or the label, is the FDA-approved document containing full trial data, adverse event tables with rates, contraindications, drug interactions, and boxed warnings. The pamphlet is marketing material produced by the manufacturer's communications department, and it is written to reassure.

You do not need permission to read the insert. Every FDA-approved prescribing information document is free and public at DailyMed, run by the National Library of Medicine, and at Drugs@FDA, so if you are told the insert is unavailable or too technical for you, that answer is wrong on both counts.

What Happens When Consent Is Not Obtained

The following cases are not edge cases. Each one involved people seeking relief who were not given information that existed at the time and would have changed their decision.

Thalidomide

Marketed from the late 1950s as a sedative and prescribed to pregnant women for morning sickness, thalidomide caused severe limb malformations and other birth defects in an estimated ten thousand infants worldwide. It was never approved for general use in the United States because FDA reviewer Frances Kelsey refused to clear it, citing insufficient safety data. The disaster produced the 1962 Kefauver-Harris Amendments, which for the first time required manufacturers to demonstrate effectiveness as well as safety and mandated informed consent from clinical trial participants.

Vioxx

Rofecoxib was approved in 1999 and prescribed to an estimated eighty million people for arthritis and pain. Merck withdrew it in 2004 after its own trial data confirmed elevated cardiovascular risk, and documents released during subsequent litigation showed the company had signals of that risk years earlier. FDA scientist David Graham estimated in testimony to the Senate Finance Committee, and later in The Lancet, that the drug contributed to tens of thousands of excess heart attacks and sudden cardiac deaths in the United States alone. Patients taking it for joint pain were not told they were accepting a cardiac risk.

Breast Implants

Women receiving implants for reconstruction or cosmetic reasons were not routinely told about the range of systemic symptoms now grouped under the term breast implant illness, including fatigue, cognitive difficulty, joint and muscle pain, and autoimmune-type presentations. The syndrome is still being characterized in the literature and its mechanism is not settled, but the disclosure failure is not in question. In 2021 the FDA required a boxed warning on all breast implants along with a patient decision checklist, which is an acknowledgment that prior consent practices were inadequate. The agency has separately confirmed breast implant associated anaplastic large cell lymphoma, a cancer linked primarily to textured implants.

LASIK

Refractive eye surgery is marketed heavily as a low-risk convenience procedure, and a subset of patients develop persistent dry eye, chronic pain, halos, starbursts, and double vision that do not resolve. The FDA's 2022 draft guidance on LASIK patient labeling explicitly directed that patients be informed of these outcomes, and it named depression and suicidal ideation among the risks requiring disclosure. Morris Waxler, the former FDA official who oversaw the original device approvals, later petitioned the agency to withdraw them, stating that adverse event rates were substantially higher than what patients were being told.

Severity is not the test. A side effect that is uncomfortable rather than catastrophic still belongs in the conversation, because the patient is the one who decides whether it is worth accepting.

---

The Placebo Problem

A trial's control arm determines what its data can tell you, and this is the single most misunderstood point in the safety conversation.

In a placebo-controlled trial, participants are randomized to receive either the product or an inert substance such as saline. Because the two groups differ in nothing except the product, any difference in adverse events between them is attributable to the product, and that is the entire purpose of the design.

When the control group receives something that is not inert, the comparison changes. Randomization still establishes cause and effect, but only relative to whatever the control group actually received. A new vaccine tested against an existing vaccine tells you how the two compare and nothing about how either compares to no injection. A vaccine tested against its own formulation minus the antigen, meaning the adjuvant, preservatives, and carrier solution on their own, leaves both arms having received the adjuvant, so no group exists that can reveal what the adjuvant contributes.

What This Means for the Childhood Schedule

In September 2025, attorney Aaron Siri testified under oath before a US Senate subcommittee on this exact question. He was responding to a database of 661 vaccine trials submitted as evidence that childhood vaccines have been placebo-tested, and after examining the trials individually he told the committee that not one of them was relied upon to license a routine injected vaccine on the CDC childhood schedule using an inert placebo. His written testimony and supporting documentation are posted publicly on the Senate committee's own website.

The COVID-19 vaccines were the exception, having used saline placebo in their pivotal trials. That comparison ended early when the placebo groups were unblinded and offered the vaccine within months of authorization, which eliminated the controlled comparison long before the planned follow-up period concluded.

The 1954 Salk polio field trial is the study most often held up as the model of a placebo-controlled vaccine trial, and it is worth reading what the trial's own final evaluation report says the control solution contained. The report describes a solution prepared to resemble the vaccine in appearance and consistency: Medium 199, with the pH adjusted so its color after the addition of phenol red matched the vaccine, antibiotics added at the same concentration used in the vaccine, and treatment with formalin which was then neutralized as it was in the vaccine. None of those components is inert, and the report states plainly that the design goal was matching the vaccine rather than isolating it.

Why the Distinction Matters to a Patient

This establishes nothing about whether any particular vaccine is safe or unsafe, and it is not an argument for or against any product. It establishes what the existing data can and cannot support.

The specific claim it cannot support is a relative one. When a provider tells a patient that receiving a given injection is safer than declining it, that statement requires a comparison between a group that received the product and a group that received nothing. Where no such group was ever enrolled, the data underlying that comparison does not exist, and the claim is coming from somewhere other than the pre-licensure trial evidence.

There is a stated reason for the design. Once a vaccine is considered established against a serious disease, regulators and ethics boards have been reluctant to randomize children to receive nothing, and that reasoning is why active comparators became standard. The reasoning is worth understanding, and it does not change what the resulting data set contains. Both things are true at once, and a patient weighing a decision is entitled to have the limitation described rather than dismissed.

Post-licensure surveillance and observational studies carry more of the weight here than most patients realize, and those methods have their own limitations, including reliance on passive reporting and the difficulty of assembling a comparable unexposed group. A patient who wants that explained before consenting is asking a reasonable question, and the answer to a reasonable question is not reassurance.

A Personal Note

I was pressured into receiving the Gardasil 9 vaccine, and no one walked me through the risks, offered me the package insert, or presented declining as a real option. I had a reaction to that injection and have dealt with the consequences for years.

What stays with me is not only the reaction but the fact that I was never given the chance to make the decision myself. Had someone handed me the insert and given me a week to read it, I would have researched it thoroughly, asked better questions, and quite possibly reached a different conclusion. That choice was taken from me, and no consent form I signed changes it.

I hear versions of this story from clients constantly, and it does not get easier to hear.

Informed Consent in Herbal Practice

Herbalists in the United States are not licensed, do not diagnose, and do not prescribe. That legal position does not remove the obligation to disclose, and if anything it raises the standard, because clients arrive assuming that natural means harmless and that assumption needs correcting before anything else happens.

What a client is owed before starting an herbal protocol:

• Known interactions with prescription medications, including anticoagulants, thyroid medication, antidepressants, and anything metabolized through cytochrome P450 pathways where an herb may raise or lower drug levels.
• Contraindications for pregnancy, nursing, specific conditions, and upcoming surgery.
• What the evidence actually supports, distinguishing traditional use from clinical trial data, and saying plainly when the evidence is thin.
• Realistic timelines, because herbs generally work gradually and a client expecting relief in three days will abandon a protocol that needed six weeks.
• Sourcing and quality, including where the plant material came from, whether it was tested, and why that matters.
• What herbal medicine cannot do, and when a condition needs a physician instead.
• Individual variation, since two people with the same presentation may respond differently to the same formula.

Telling a client that an herb is not appropriate for their situation, or that they need diagnostic imaging rather than a tincture, is part of the same duty, because consent is meaningless if the alternatives were never mentioned.

When the Herbalist Fills the Gap

A large share of my consultations now include information a client should have received from their physician. They arrive on a medication and do not know it carries a boxed warning, or they were prescribed something without being told what the alternatives were, or they asked for the insert and were handed a brochure.

This is not my job, since I am not their prescriber, did not order the medication, and have no role in that decision. When a client asks me directly what a drug does and no one else has told them, I am not going to pretend I do not know how to look it up.

So I show them how to find the insert themselves, explain how to read the adverse reactions table and what the percentages mean, and help them write down questions for their next appointment, all of which is education and stays firmly inside my scope. What I do not do is tell anyone to stop a prescribed medication, contradict a diagnosis, or substitute my judgment for their physician's. The goal is a client who walks back into that office able to ask the right questions, not one who walks away from care.

None of this reflects badly on individual physicians, most of whom are working inside a system that gives them fifteen minutes and penalizes them for taking twenty. Many have not read the full insert for every drug they prescribe, because reading them all is not possible at the volume they are expected to maintain, so the failure is structural even though the consequences land on patients.

How to Get Informed Consent From Your Doctor

• Ask for the package insert by name. Request the prescribing information rather than the patient leaflet, and if the office will not provide it, look the drug up at DailyMed or Drugs@FDA before you fill the prescription.
• Ask directly whether there is a boxed warning. Phrase it exactly that way.
• Ask what the alternatives are, including doing nothing. Watchful waiting is a legitimate option for many conditions and is frequently omitted.
• Ask what the trial evidence showed. Specifically, what the product was compared against, and whether benefit was measured on a real outcome or a surrogate marker.
• Ask what happens if you decline. A provider who cannot answer this without applying pressure is not obtaining valid consent.
• Take time. Outside genuine emergencies you can leave with the prescription unfilled and decide at home, because no rule requires you to consent in the room.
• Write it down. Bring your questions on paper so a short appointment does not end before you have asked them.

Frequently Asked Questions

Is informed consent a legal requirement in the United States?

Yes. Every state requires it in some form for medical treatment, and federal regulation at 21 CFR 50.25 sets specific disclosure requirements for clinical trial participation. The details of what must be disclosed vary by state.

Does signing a consent form mean I gave informed consent?

Not necessarily. The form documents that a conversation took place, and consent is only valid if the disclosure was adequate and the decision was voluntary. Consent obtained through pressure or incomplete information is not valid regardless of what was signed.

How do I get the FDA package insert for my medication?

Search the drug name at DailyMed, run by the National Library of Medicine, or at Drugs@FDA. Both are free and public, and neither requires a prescription or a request through your doctor's office.

What is the difference between the package insert and the pamphlet from my doctor?

The package insert is the FDA-approved label containing full trial data, adverse event rates, contraindications, interactions, and any boxed warning. The pamphlet is manufacturer marketing material written for reassurance, and it is not a substitute.

What is a black box warning?

It is the strongest safety alert the FDA issues, reserved for risks that can cause serious injury or death, and it appears at the top of the prescribing information inside a black border. Ask your prescriber directly whether the drug you are being given carries one.

Can I refuse a treatment my doctor recommends?

Yes. The right to decline is part of informed consent, and outside of narrow emergency and public health exceptions the decision belongs to you. You are also entitled to be told what happens if you decline.

Why does the control group in a clinical trial matter?

Because the control group determines what the results can be compared to. If the control group received an inert substance, differences in adverse events point to the product. If the control group received something active, the trial can only tell you how the two compare to each other.

Do herbalists have to obtain informed consent?

Herbalists are not licensed in the United States and do not diagnose or prescribe, but the ethical obligation to disclose interactions, contraindications, evidence quality, and limitations applies regardless of licensure.

Where This Leaves Us

Informed consent came out of the worst thing organized medicine has ever done, and it was written into law precisely so that convenience could never override it. That history is worth remembering whenever disclosure is treated as a form to be completed rather than a conversation to be had.

Every case above involved information that existed at the time and was not passed on, and the people harmed were not asking for anything unusual. They wanted to know what they were agreeing to.

Ask for the insert, read it, ask what you are not being told, and take the time you need to decide. Your health decisions belong to you, made freely and with full information, in consultation with providers who respect that they are yours to make.

Sources

• Nuremberg Code, 1947. Reproduced in Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10, Vol. 2.
• Schloendorff v. Society of New York Hospital, 211 N.Y. 125 (1914).
• Salgo v. Leland Stanford Jr. University Board of Trustees, 154 Cal. App. 2d 560 (1957).
• Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972).
• The Belmont Report, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979.
• 21 CFR 50.25, Elements of informed consent. US Food and Drug Administration.
• Francis T. Jr. Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine: Final Report. Chapter III, Conduct of the Field Trial, p. 51, Vaccine-Placebo Code Scheme.
• Siri A. Written testimony submitted to the United States Senate Committee on Homeland Security and Governmental Affairs, September 5, 2025. hsgac.senate.gov. See also the May 19, 2025 submission.
• Graham D. Testimony before the US Senate Committee on Finance, November 18, 2004, and Graham et al., The Lancet, 2005.
• US Food and Drug Administration. Breast implant labeling recommendations, boxed warning and patient decision checklist, October 2021.
• US Food and Drug Administration. Draft guidance: Laser-Assisted In Situ Keratomileusis (LASIK) Lasers, Patient Labeling Recommendations, July 2022.
• US Government Accountability Office and HHS Office of Inspector General reports on accelerated approval confirmatory trials.
• DailyMed, National Library of Medicine. dailymed.nlm.nih.gov.